Amarin appeals ‘skinny label’ loss


Staff Writer

Amarin appeals ‘skinny label’ loss

Pavel Kapysh /

Generic heart drug was found to not infringe Amarin’s blockbuster treatment earlier this year | Health insurer Health Net also tied to the original case after allegedly promoting use of the generic.

Hikma Pharmaceuticals, Amarin Pharmaceuticals, Vascepa, generics, skinny label, patent infringement